Navigation Links
FDA Approves New Injectable Osteoporosis Treatment for Postmenopausal Women
Date:6/1/2010

SILVER SPRING, Md., June 1 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Prolia, an injectable treatment for postmenopausal women with osteoporosis who are at high risk for fractures.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO )

Osteoporosis is a disease in which the bones become weak and are more likely to break. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, 80 percent of the people in the United States with osteoporosis are women. One out of every two women over age 50 will break a bone in their lifetime due to osteoporosis.

People with osteoporosis at high risk for fracture include those that have had an osteoporotic fracture, or have multiple risk factors for fracture; or those who have failed or are intolerant to other available osteoporosis therapy. Prolia works to decrease the destruction of bone and increase bone mass and strength. An injection of Prolia is recommended once every six months.

"Due to its prevalence, osteoporosis is a serious concern to public health," said Julie Beitz, M.D., director of the FDA's Office of Drug Evaluation III. "The approval of Prolia provides another treatment option for postmenopausal women with osteoporosis who are susceptible to fractures."

The safety and efficacy of Prolia in the treatment of postmenopausal osteoporosis was demonstrated in a three-year, randomized, double-blind, placebo-controlled trial of 7,808 postmenopausal women ages 60 to 91 years. In the study, Prolia reduced the incidence of vertebral, non-vertebral, and hip fractures in postmenopausal women with osteoporosis.

The most common side effects reported with Prolia include back pain, pain in the extremities, musculoskeletal pain, high cholesterol levels, and urinary bladder infections. Serious adverse reactions include hypocalcaemia (low calcium levels in the blood), serious infections, including infections of the skin, and dermatologic reactions such as dermatitis, rashes, and eczema.

Prolia causes significant suppression of bone turnover and this suppression may contribute to the occurrence of osteonecrosis of the jaw, a severe bone disease that affects the jaw, atypical fractures, and delayed fracture healing.

Prolia was approved with a risk evaluation and mitigation strategy (REMS) that includes a Medication Guide for patients and communications to health care providers that explains the risks and benefits of the drug.

Prolia is manufactured by Amgen Manufacturing Limited, a subsidiary of Thousand Oaks, Calif.-based Amgen Inc.

For more information

Fast Facts on Osteoporosis – National Institute of Arthritis and Musculoskeletal and Skin Diseases

http://www.niams.nih.gov/Health_Info/Bone/Osteoporosis/osteoporosis_ff.asp

Media Inquiries: Elaine Gansz Bobo, 301.796.7567, elaine.bobo@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves New Treatment for Late-Onset Pompe Disease
2. FDA Approves Cefepime for Use In B. Brauns DUPLEX(R) System
3. U.S. FDA Approves Natazia(TM), a New Oral Contraceptive for the Prevention of Pregnancy
4. FDA Approves New Combination Product Oral Contraceptive
5. FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD
6. FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer
7. FDA Approves New Device for Adults with Severe and Persistent Asthma
8. FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels
9. FDA Approves First of Its Kind, Fully Implantable (Surgically), Invisible, Prosthetic Hearing Restoration Device
10. FDA Approves First Totally Implanted Hearing System
11. FDA Approves Watsons TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 23, 2017  HealthMine surveys with 9,250 insured consumers ... health plan members want help from their plans in ... in their health, 2) help closing gaps in care, ... health and 5) relevant, real-time guidance. Meeting these needs ... costs. A Reason to Stay ...
(Date:3/23/2017)... , Mar 23, 2017 Research and Markets ... & Trends - Industry Forecast to 2025" report to their ... The ... around 6.9% over the next decade to reach approximately $3.5 billion ... and forecasts for all the given segments on global as well ...
(Date:3/23/2017)... LONDON , March 23, 2017 ... comprehensive research report created through extensive primary research ... research, the report aims to present the analysis ... basis of Procedure (Replacement and Repair); Replacement Procedure ... (TAVR)), Repair By Technique (Surgical Devices, Balloon Valvuloplasty, ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... As the ... create a communications platform that positions them as the go-to thought leader in ... their online publication as an always-on, always-fresh news, views and advocacy engine, called ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... ( http://www.hygieacare.com ) announced their partnership to prep patients for colonoscopy at the ... Endoscopy Centers in 87th Ave., Miami, FL. , The HyGIeaCare® Prep, ...
(Date:3/24/2017)... ... 2017 , ... “Vintage and Harvest A Cultivation of Christian Love” is the ... in North Carolina with his wife, Anna Marie. He and his wife are the ... is also the author of “Shadow and Substance.” , “Love, the agape kind, is ...
(Date:3/23/2017)... Houston, Texas (PRWEB) , ... March 23, 2017 , ... ... their 3rd location in the greater Houston Area. The new location is located at ... St. Luke’s Hospital in Springwoods Village. This newest location will provide patients living in ...
(Date:3/23/2017)... New Holland, PA and Grimsby, Ontario (PRWEB) , ... March 23, 2017 , ... The ... to the modular industry or whose acts have had a significant impact on the careers ... of Sales and Marketing with NRB Inc. was inducted into the MBI’s Hall of Fame. ...
Breaking Medicine News(10 mins):